Real stories. Real impact. A better world.
GOOD NEWS DAILY
AllAnimalsCommunityEconomyEnvironmentHealthHumanityInnovationScienceWeekly Recap

Uganda Gives First Doses of an Experimental Vaccine Against the Bundibugyo Ebola Virus

Volunteers in Masaka, Uganda, have received the first doses of ChAdOx1 BDBV, an Oxford-developed vaccine against Bundibugyo virus disease, a severe form of Ebola that has no licensed vaccine. The phase I trial will test safety and immune response.

By , Editor

· Uganda · 1 min read

Source: The Eastleigh Voice ↗
Share
A syringe lying beside small glass vaccine vials on a white surface
A syringe lying beside small glass vaccine vials on a white surface. Photo: MasterTux (Pixabay)

Researchers in Uganda have given the first doses of an experimental vaccine against Bundibugyo virus disease, a severe form of Ebola for which no licensed vaccine exists, The Eastleigh Voice reported. The first volunteers were vaccinated in Masaka City on October 6 in a trial run by the MRC/UVRI and LSHTM Uganda Research Unit.

The phase I trial checks safety and immune response first

The study is testing ChAdOx1 BDBV, developed at the University of Oxford’s Oxford Vaccine Group and Pandemic Sciences Institute. This first stage will look at whether the vaccine is safe and whether it triggers an immune response in healthy adults. It will not yet show whether the vaccine prevents infection or illness, which requires larger, later-stage trials.

The vaccine uses the same ChAdOx viral-vector platform as the Oxford/AstraZeneca COVID-19 vaccine: a modified chimpanzee adenovirus carries genetic information from the target virus to train the immune system. The world’s first human trial of the vaccine began in the UK on July 24, according to Digital Journal.

Doses are already stockpiled

The Serum Institute of India has manufactured and stockpiled about 620,000 doses, produced within two weeks, Oxford and the institute said. About 3,000 doses have been supplied for the Ugandan study.

An outbreak gave the work new urgency

Vaccines exist for Ebola disease caused by the Zaire ebolavirus, but not for Bundibugyo. Interest grew after the World Health Organization was alerted on May 5 to a high-mortality outbreak in the Democratic Republic of the Congo, later confirmed as Bundibugyo virus disease. The WHO puts Ebola’s average fatality rate at about 50%, though it varies widely between outbreaks.

If later trials show it works, a vaccine would add to existing tools such as surveillance, contact tracing, medical care and infection control. Keeping vaccines cold is another hurdle in outbreaks, and MIT researchers have used AI to design mRNA vaccines that stay stable for a year at room temperature, so far tested in mice.

Not medical advice. This article reports on research and health programs for general information. Results from early studies often change in larger trials. Talk to a doctor before making decisions about your own health or treatment.

Sources

How we choose and verify sources: editorial policy.

More stories: Good news from clinical trials (16) →

Explainer: What are the phases of a clinical trial? →

Your weekly dose of good news

The 5 biggest positive stories of the week, straight to your inbox. Free, no noise.